Biotech Stocks Dominate Monday’s Top 10 Gainers

4. Certara Inc. (NASDAQ:CERT)

Shares of Certara Inc. surged by 11.54 percent on Monday to finish at $14.40 apiece as investors cheered the company’s launch of its Non-Animal Navigator (NAN) solution, supporting the Food and Drug Administration’s (FDA) decision last week to reduce animal testing in preclinical safety studies.

According to CERT, the NAN is a flexible solution that offers strategic regulatory advice, an integrated preclinical development plan, and an optimized AI-enabled modeling toolkit, all of which would ensure that clients’ development programs “are compliant, agile, and future-ready.”

“The FDA announcement and roadmap pave the way for more model-informed drug development approaches that are predictive, efficient, and ethical,” said CERT Chief Executive Officer William F. Feehery. ”It is part of a growing industry adoption trend to use scientifically robust new approach methodologies (NAMs) like AI-enabled biosimulation to improve strategic decision-making and success rates at every phase of drug development.”

CERT is a company engaged in biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.